Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and rare autoimmune diseases. The Company's proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like receptors (TLRs). In addition to its TLR programs, it is developing gene silencing oligonucleotides (GSOs) that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA.

Type
Public
HQ
Cambridge, US
Founded
1989
Size (employees)
62 (est)
Idera Pharmaceuticals was founded in 1989 and is headquartered in Cambridge, US
Report incorrect company information

Key People/Management at Idera Pharmaceuticals

Sudhir Agrawal

Sudhir Agrawal

Chief Executive Officer and President, Board of Directors
Louis J. Arcudi

Louis J. Arcudi

Senior Vice President of Operations, Chief Financial Officer, Treasurer, and Secretary
Robert D. Arbeit

Robert D. Arbeit

Vice President, Clinical Development
Timothy M. Sullivan

Timothy M. Sullivan

Vice President, Development Programs and Alliance Management

Idera Pharmaceuticals Office Locations

Idera Pharmaceuticals has offices in Cambridge and Exton
Cambridge, US (HQ)
167 Sidney Street
Exton, US
505 Eagleview Blvd, Suite 212
Show all (2)
Report incorrect company information

Idera Pharmaceuticals Financials and Metrics

Idera Pharmaceuticals Financials

Idera Pharmaceuticals's revenue was reported to be $249 k in FY, 2015 which is a 241.1% increase from the previous period.
USD

Net income (FY, 2017)

(66 m)

EBIT (FY, 2017)

(66.5 m)

Market capitalization (18-Apr-2018)

278.1 m

Cash (31-Dec-2017)

112.6 m

EV

165.6 m
Idera Pharmaceuticals's current market capitalization is $278.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

47 k73 k249 k

Revenue growth, %

55%241%

General and administrative expense

16.7 m

R&D expense

50.7 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

General and administrative expense

3.8 m4 m3.9 m3.8 m3.9 m4.1 m3.9 m

R&D expense

9 m7.5 m9.3 m10.1 m9.4 m11.5 m17.9 m

Operating expense total

12.8 m11.5 m13.2 m13.9 m13.3 m15.6 m21.8 m

EBIT

(12.8 m)(11.5 m)(12.9 m)(13.6 m)(13 m)(15.2 m)(21.6 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

26.3 m20 m26.6 m80.7 m112.6 m

Accounts Receivable

Inventories

874 k1.2 m3.1 m2 m

Current Assets

30.3 m42.4 m63.2 m111 m116.6 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(18.2 m)(38.6 m)(48.6 m)(38.4 m)

Depreciation and Amortization

137 k206 k488 k656 k

Inventories

(676 k)(329 k)(1.9 m)1.1 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(12.7 m)(11.4 m)(12.8 m)(13.5 m)(12.9 m)(15.1 m)

Accounts Payable

2.8 m881 k958 k629 k344 k1.4 m529 k
USDY, 2017

EV/EBIT

-2.5 x

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information